The estimated Net Worth of Richard T Schumacher is at least $358 Tisíc dollars as of 24 December 2018. Mr. Schumacher owns over 1,500 units of Pressure BioSciences stock worth over $1,061 and over the last 20 years he sold PBIO stock worth over $0. In addition, he makes $357,263 as Director at Pressure BioSciences.
Richard has made over 15 trades of the Pressure BioSciences stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 1,500 units of PBIO stock worth $3,015 on 24 December 2018.
The largest trade he's ever made was buying 109,589 units of Pressure BioSciences stock on 7 February 2012 worth over $99,726. On average, Richard trades about 3,226 units every 61 days since 2005. As of 24 December 2018 he still owns at least 38,583 units of Pressure BioSciences stock.
You can see the complete history of Mr. Schumacher stock trades at the bottom of the page.
Richard T. Schumacher serves as Director of the Company. He is no longer President, Chief Executive Officer, Treasurer, Secretary, Clerk of Pressure BioSciences, Inc., effective September 9, 2019. He is the founder of the Company, and has served as a director of the Company since 1978. He has served as the Company’s Chief Executive Officer since April 16, 2004 and President since September 14, 2004. He previously served as Chief Executive Officer and Chairman of the Board of the Company from 1992 to February 2003. From July 9, 2003 until April 14, 2004 he served as a consultant to the Company pursuant to a consulting agreement. He served as President of the Company from August 1978 to August 1999. Mr. Schumacher served as the Director of Infectious Disease Services for Clinical Sciences Laboratory, a New England-based medical reference laboratory, from 1986 to 1988. From 1972 to 1985, Mr. Schumacher was a research scientist and clinical laboratory director at the Center for Blood Research, a nonprofit medical research institute associated with Harvard Medical School. Mr. Schumacher received a B.S. in Zoology from the University of New Hampshire.
As the Director of Pressure BioSciences, the total compensation of Richard Schumacher at Pressure BioSciences is $357,263. There are no executives at Pressure BioSciences getting paid more.
Richard Schumacher is 69, he's been the Director of Pressure BioSciences since 2019. There are 2 older and 5 younger executives at Pressure BioSciences. The oldest executive at Pressure BioSciences, Inc. is Richard T. Schumacher, 71, who is the Founder, Pres, CEO, Treasurer, Interim CFO, Clerk & Director.
Richard's mailing address filed with the SEC is 130 Lake Ridge Dr, Taunton, MA 02780, USA.
Over the last 21 years, insiders at Pressure BioSciences have traded over $0 worth of Pressure BioSciences stock and bought 433,961 units worth $321,010 . The most active insiders traders include Gregory Gene Freitag, Richard T Schumacher a Kevin W Quinlan. On average, Pressure BioSciences executives and independent directors trade stock every 111 days with the average trade being worth of $342. The most recent stock trade was executed by Bradford Addison Young on 31 December 2018, trading 1,579 units of PBIO stock currently worth $3,553.
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the Americas, Europe, Asia, Africa, and Australia. Its pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. It serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. Pressure BioSciences, Inc. has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts.
Pressure BioSciences executives and other stock owners filed with the SEC include: